Neuron-derived molecules are potent regulators of oligodendrocyte differentiation and myelination during brain development and upon demyelination. Their analysis will thus contribute to understanding remyelination failure in demyelinating diseases, such as multiple sclerosis (MS). Previously, we have identified neuronal galectin-4 as a novel negative soluble regulator in the timing of developmental myelination. Here, we investigated whether galectin-4 is re-expressed in axons upon demyelination to regulate the timing of remyelination. Our findings revealed that galectin-4 is transiently localized to axons in demyelinated areas upon cuprizone-induced demyelination. In contrast, in chronic demyelinated MS lesions, where remyelination fails, galectin-4 is permanently present on axons. Remarkably, microglia/macrophages in cuprizone-demyelinated areas also harbor galectin-4, as also observed in activated microglia/ macrophages that are present in active MS lesions and in inflammatory infiltrates in chronic-relapsing experimental autoimmune encephalomyelitis. In vitro analysis showed that galectin-4 is effectively endocytosed by macrophages, and may scavenge galectin-4 from oligodendrocytes, and that endogenous galectin-4 levels are increased in alternatively interleukin-4-activated macrophages and microglia. Hence, similar to developmental myelination, the (re)expressed galectin-4 upon demyelination may act as factor in the timing of oligodendrocyte differentiation, while the persistent presence of galectin-4 on demyelinated axons may disrupt this fine-tuning of remyelination.
INTRODUCTION
Multiple sclerosis (MS) is an inflammatory, demyelinating and degenerative disease of the central nervous system (CNS) (1, 2) . While remyelination occurs frequently at early stages of MS, it generally fails at later stages, although remyelination is observed in some patients at late-stage progressive MS (3) (4) (5) . Remyelination involves the recruitment of activated oligodendrocyte progenitor cells (OPCs) to demyelinated areas, followed by their differentiation into mature oligodendrocytes (OLGs) and enwrapment of newly formed myelin around the demyelinated axons (6) . Why remyelination generally fails in MS lesions is still unknown, but both aging and a dysregulated signaling environment are important determinants (6) . Likely for most lesions, not the recruitment of OPCs, but rather an altered microenvironment in the lesioned area seems to contribute to an impaired differentiation of OPCs to mature myelinating OLGs (7, 8) .
Myelination is a tightly regulated and balanced process that involves spatial and sequential appearance of multiple interacting environmental signals. During developmental myelination, OPC differentiation is mainly orchestrated by both positive and negative regulatory signals derived from axons (9) (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) . As remyelination is seen as a recapitulation of developmental myelination (6, 20) , most axonal regulators of OPC differentiation are re-expressed upon demyelination to enable the fine-tuning of OPC differentiation during remyelination (11, 21, 22) . Next to (reexpressed) axonal-derived signals, signals from (activated) microglia and macrophages play a prominent role in OPC differentiation upon remyelination (23) (24) (25) (26) . Guided by microenvironmental signals generated upon demyelination, a continuum of dynamic states of resident microglia and infiltrated blood-derived macrophages exists. Intriguingly, the predominance of alternatively activated microglia and macrophages at the onset of remyelination is essential for OPC differentiation to proceed (25) .
Neuronal galectin-4 is a novel player in the regulation of the timing of OPC differentiation during CNS development (27) . As receptor for distinct glycoconjugates, that is, sulfatide and glycoproteins with N-acetyllactosamine termini at Nglycans, it can translate the presence of glycan-encoded signals into bioactivities, such as glycoprotein routing (28) (29) (30) (31) . Galectin-4 belongs to the tandem-repeat-type group of galectins (32) (33) (34) (35) that are defined by a modular architecture of 2 distinct carbohydrate recognition domains connected via a linker. This way, it can cross-link 2 types of receptors, the lectin thereby acting as molecular bridge, as shown in aggregation and raft organization assays (36, 37) . We have previously demonstrated that non-myelinated neurons express and secrete galectin-4 that leads to an arrest in OPC differentiation, indicating that neuronal galectin-4 is a negative regulator of myelination (27) . At the same time, endogenous neuronal galectin-4 organizes the transport and spatial organization of glycoprotein L1 at the axon (38) . Correct delivery of L1 is required for proper axon growth, and ligation of axonal L1 with oligodendroglial F3/contactin initiates translation of myelin basic protein (MBP) (39, 40) , a myelin-specific protein imperative for myelination to occur. In addition, galectin-4-containing domains on developing axonal membranes repel myelin deposition (41) . The arrangement of these galectin-4-containing domains is regulated by neurons and myelin-independent. In developing OLGs, localization of oligodendroglial galectin-4 shifts from the cytoplasm to the nucleus to regulate MBP promoter activity upon OPC maturation (27, 42) . In contrast to neurons, galectin-4 is not released by OLGs (27) . Thus, galectin-4 appears to be able to act at several sites to control myelination. In the present study, we aimed to identify whether galectin-4 might fulfill a regulatory role upon demyelination. We determined the presence of galectin-4 in MS-relevant experimental animal models, including cuprizone-induced demyelination and chronic-relapsing experimental autoimmune encephalomyelitis (cr-EAE) and human MS lesions. Our findings revealed that upon demyelination galectin-4 is transiently re-expressed in axons, and in contrast to developmental myelination, galectin-4 is also present in activated microglia/macrophages. Accordingly, we analyzed galectin-4 binding, uptake and expression in classically and alternatively activated bone marrow-derived macrophages (BMDMs) and microglia in vitro. Interestingly, in chronic MS lesions where remyelination fails, axonal galectin-4 is persistently present. Hence, interventions aimed at antagonizing the effect of galectin-4 on OPC maturation may promote remyelination in MS lesions.
MATERIALS AND METHODS

MS Lesions
Human Autopsy Brain Material
Autopsy samples of human brain material were obtained from the Netherlands Brain Bank and with the approval of the VU University Medical Ethical Committee (Amsterdam, the Netherlands). All donors from whom material was collected had signed written informed consent for brain autopsy and the use of material and clinical information for research purposes. Human postmortem brain material was obtained from 25 patients with clinically diagnosed and pathologically confirmed MS (14 [chronic] active lesions, 9 chronic inactive lesions, and 2 remyelinated lesions) and from 11 control subjects without neurological diseases according to a procedure as described (43) . Characteristics of the used brain autopsy material, identification and classification of white matter lesions have been described (44) .
Immunohistochemistry
Deparaffinized paraffin-embedded sections (5 mm) were incubated in 10 mM citrate buffer (pH 6) at 125 C for 10 minutes, followed by an incubation with 0.5 M sodium acetate for 5 minutes at room temperature (RT). Cryosections (10 mm) were fixed in acetone for 10 min at RT. Unspecific binding was blocked with 10% normal goat serum (NGS; Vector Laboratories, Burlingame, CA) and 0.3% Triton X-100 (TX100) for 1 hour at RT. Sections were incubated with primary antibodies (Table) overnight at 4 C, followed by incubation with appropriate secondary antibodies (Dako Real EnVision/HRP, Rabbit/Mouse K5007, DakoCytomation, Glostrup, Denmark) for 30 minutes at RT. Peroxidase activity was visualized with 30% (w/v) 3,3 0 -diaminobenzidine (DAB, Sigma, St. Louis, MO) in Trisbuffered saline (TBS) containing 0.03% H 2 O 2 . Sections were counterstained with hematoxylin and analyzed with a bright-field BX50 Olympus microscope using Cell B software. For double-immunohistochemical fluorescence staining, acetone-fixed cryosections were first incubated with anti-galectin-4 antibodies overnight at 4 C, followed by a 1-hour incubation with the other primary antibodies. Sections were incubated with their respective Alexa-labeled secondary antibodies (1:400), and the nuclei were stained with 4 0 ,6-diamidino-2-phenylindole ([DAPI], 1 mg/mL, Sigma) for 1 hour at RT. The home-made anti-galectin-4 antibody was systematically tested against other galectin family members by ELISA and by Western blot (galectins-1, -2, -3, -7, -8, and -9, data not shown, [45] ), and cross-reactive material had been removed by affinity chromatography to ensure specificity. Furthermore, when tissue was incubated with an anti-galectin-4-recombinant galectin-4 complex, no staining was observed and no galectin-4-immunoreactive band appears on Western blot of lysates of cells that do not express galectin-4, for example, astrocytes (data not shown). Sections were analyzed with a confocal laser scan microscope Leica SP2 AOBS CLSM equipped with Leica Confocal Software. Profiles of fluorescence were recorded sequentially and processed using Fiji (46) and Adobe Photoshop CS6.
Cuprizone-Induced Demyelination
Animals
Experimental animal protocols for the cuprizone demyelination model and primary cell cultures were approved by the Institutional Animal Care and Use Committee of the University of Groningen (the Netherlands). All methods were carried out in accordance with national and local experimental animal guidelines and regulations. To induce demyelination, 8-to 10-week-old adult male C57Bl/6 mice (Harlan) were fed 0.2% cuprizone (bis-cyclohexanone oxalhydrozone, Sigma) mixed into standard rodent chow for 5 weeks. After 5 weeks of cuprizone-supplemented chow, mice were fed a standard chow diet for 2 weeks to induce remyelination. Cuprizone-fed animals were killed after 3 or 5 weeks feeding and after 2 days, 7 days or 2 weeks remyelination. Control animals were kept at the same conditions for 7 weeks without cuprizone feeding.
Tissue Preparation and Selection
For biochemical analysis, the corpus callosum was dissected and homogenized using a Wheaton homogenizer in icecold TE buffer (10 mM Tris-HCl, 2 mM EDTA, 0.25 M sucrose, and a cocktail of protease inhibitors [Complete Mini; Roche Diagnostics, Mannheim, Germany]). For immunohistochemical purposes, both fresh-frozen and perfused tissue samples were used. Animals were anesthetized and intracardially perfused with phosphate-buffered saline (PBS), followed by 4% paraformaldehyde (PFA) in PBS (pH 7.4). PFA-perfused brains were cryoprotected in 20% sucrose in PBS at 4 C for 1-3 days, and afterward embedded in Tissue-Tek (Sakura Finetek Europe, Alphen aan de Rijn, the Netherlands) and frozen on dry ice. For fresh-frozen tissue, brains were dissected out and snap-frozen in isopentane, which was kept on dry ice. All brains were kept at À80 C until used for cryostat sectioning. Using the Allen Mouse Brain Atlas (47) as a reference, sections of brain and corpus callosum were studied at the level of 59-63 of the Atlas. De-and remyelinated areas were characterized by the myelin stain Luxol fast blue (LFB).
Immunohistochemistry
Fresh-frozen brain sections (16 lm) were air-dried for 10 minutes followed by acetone fixation for 10 minutes at RT. PFA-perfused brain sections (12 mm) were immersed in citrate buffer (pH 6.0; Sigma) and heated for 20 minutes at 100 C. Sections were blocked with 5% NGS in PBS for 2 hours at RT or with 5% normal donkey serum and 0.1% TX100 for 30 minutes (anti-Olig2 and Iba1 antibodies) at RT and incubated with primary antibodies (Table) overnight at 4 C. Sections were incubated with their respective Alexa-labeled secondary antibodies (1:400, Invitrogen, Carlsbad, CA) and DAPI for 1 hour at RT. To determine the extent of de-and remyelination, sections were stained with Sudan Black (0.1% in 70% ethanol) for 10-15 minutes. Immunofluorescence was visualized on a Leica TCS SP8 Confocal Laser Scanning Microscope. Fluorescence intensity (mean gray values without background subtraction) was measured drawing an ROI of the whole corpus callosum on each condition using Fiji. Measurements were set on integrated density, and 3-4 animals per condition were analyzed. To combine data of fluorescent intensities, 1 control condition was set to 100% in sections of perfused and snap-frozen specimen and relative intensity levels were determined.
In Situ Hybridization
The digoxigen-labeled proteolipid protein (PLP) probe was generated as described (48) . The probe (1:1000) was diluted in hybridization buffer (formamide 50%, 200 mM NaCl, 5 mM EDTA, 10 mM Tris-HCl, 5 mM NaH 2 PO 4 x2H 2 O, 5 mM Na 2 HPO 4 , yeast RNA [Sigma; 100 mg/mL], 10% dextran sulfate, 1Â Denhardts solution in diethyl pyrocarbonatetreated H 2 O). Before use, the RNA probe was denatured for 5-10 minutes at 75 C. Sections were hybridized with the RNA probe overnight at 65 C. Sections were then washed 3 times in washing buffer (1Â saline citrate buffer; 50% formamide and 0.1% Tween-20) at 65 C, and incubated with MABT (100 mM maleic salt pH 7.5, 150 mM NaCl, and 0.1% Tween-20) at RT twice for 30 minutes. Sections were blocked for 1 hour with blocking buffer (1Â MABT, 2% blocking reagent [Roche] , and 10% sheep serum), after which sections were incubated overnight with alkaline phosphatase-conjugated sheep anti-DIG Fab fragments (Roche) in blocking buffer at 4 C. After washing with MABT, hybrids of RNA were visualized with a mix of nitro blue tetrazolium/5-bromo-4-chloro-3-indolylphosphate-alkaline phosphatase and 10% poly(vinyl alcohol). Sections were washed with water and mounted with DPX mounting medium (Sigma). Staining was monitored using an Olympus bright field BX50 DIC microscope, and images were acquired with the Olympus CellB program.
Chronic Experimental Autoimmune Encephalomyelitis
Animals
All experimental procedures for the cr-EAE studies were approved by the local Animal Ethical Committee of the (49) .
Immunohistochemistry
Fresh-frozen rat spinal cord cryosections (10 mm) were air-dried for 1 hour at RT. Endogenous peroxidase was blocked with 0.3% H 2 O 2 in 50 mM in TBS (pH 7.4) for 15 minutes at RT. Unspecific staining was blocked by a solution of 5% nonfat dried milk in TBS containing 0.5%. Sections were incubated with primary antibodies (Table) overnight at 4 C, followed by an incubation for 1 hour at RT in DAKO Real EnVision/HRP. Immunoreactivity was visualized using 0.5 mg/mL DAB in Tris-HCl containing 0.03% H 2 O 2 . Sections were counterstained with hematoxylin, dehydrated in series of alcohol, followed by xylene, and mounted in Entellan. For immunofluorescent double stainings, cryosections were fixed with acetone for 10 minutes at RT, blocked in 5% NGS and stained with the activated macrophage/microglia marker ED1 (Table) overnight at 4 C, followed by secondary Alexalabeled antibody (1:400) for 45 minutes at RT. Sections were incubated with 0.1% TX100 for 30 minutes at RT, incubated with anti-galectin-4 antibody (Table) overnight at 4 C, after which galectin-4 staining was visualized with appropriate Alexa-conjugated antibodies (1:400). Nuclei were stained with DAPI (1 mg/mL). Sections were analyzed with a conventional fluorescence microscope (Provis AX70; Olympus) equipped with analySIS software.
Primary Cell Cultures
Microglia and BMDMs
Cortical primary mixed glial cultures were generated from brain tissue obtained from newborn Wistar rats as described (50) . Microglial cells were harvested by collecting the floating fraction after a 1-h shake-off procedure at 37 C at 150 rpm. BMDMs were isolated from leg bones (femur and tibia) of newborn rats and flushed with BMDM medium (RPMI supplemented with 10% fetal bovine serum, 1% sodium pyruvate, and 1% penicillin/streptomycin). Isolated microglia and BMDMs were plated at a density of 2-3 Â 10 6 cells/55 cm 2 in culture medium supplemented with rat recombinant macrophage colony-stimulated factor (10 ng/mL; PeproTech, London, UK) before activation. On day 6 (BMDMs) or day 7 (microglia), cells were gently scraped and plated on dishes at densities of 1 Â 10 6 cells/9 cm 2 /6 mL or on 13-mm coverslips at densities of 9 Â 10 4 cells/500 mL and stimulated for 48 hours with lipopolysaccharide (LPS, 200 ng/mL; Sigma) and rat interferon-c (IFN-c, 2000 U/mL; PeproTech) to induce classically activated microglia/BMDMs or stimulated with rat interleukin-4 (IL-4, 40 ng/mL; PeproTech) to induce alternatively activated microglia/macrophages. Control microglia/macrophages were not stimulated. At the start of the experiments, microglia and BMDM cultures were typical 95% pure, as assessed by immunocytochemistry using Iba1 (Abcam, Cambridge, UK) and the GSA isolectin-B4 (Invitrogen).
Immunocytochemistry PFA-fixed cells were permeabilized with 4% bovine serum albumin and 0.1% TX100 for 30 minutes. Cells were incubated for 5 hours with anti-galectin-4 antibody (Table) at RT, and incubated for 25 minutes with appropriate TRITC-labeled secondary antibody (1:50; Jackson ImmunoResearch, Inc., West Grove, PA). Cells were analyzed with a Leica DMI 6000 B microscope.
Uptake and Binding Assays
Live cells were incubated with biotinylated galectin-4 (20 mg/mL) for 30 minutes at 4 C (binding) or with Alexa-555-labeled galectin-4 (20 mg/mL) for 30 minutes at 37 C (uptake). Biotinylated galectin-4 was visualized with TRITClabeled streptavidin (1:50; Jackson ImmunoResearch). Cells were subsequently washed and fixed with 4% PFA. To inhibit carbohydrate-mediated uptake or binding of galectin-4, a mixture of the glycoprotein asialofetuin (ASF, 1.3 mg/mL) that has up to 9 galectin-reactive N-acetyllactosamine termini (51) and lactose (7 mM) was preincubated with labeled galectin-4 for 30 minutes at 37 C prior to its addition to the cells. Nuclei were stained with DAPI (1 mg/mL). Cells were analyzed with a Leica TCS SP8 Confocal Laser Scanning Microscope. The results were expressed as percentage of galectin-4-positive cells in the entire cell population.
Western Blotting
Western blotting was performed as described previously (52) . Equal amounts of proteins present in tissue homogenates (30 mg), cell lysates (50 mg), and equal volume of trichloroacetic acid-precipitated medium (250 mL) were loaded. Primary antibodies (Table, [53] ) were incubated overnight at 4 C, followed by a 1-hour incubation with appropriated IRDyelabeled secondary antibodies (1:3000, Li-Cor Biosciences, Lincoln, NE). Proteins were visualized with the Odyssey Infrared Imaging System (Li-Cor Biosciences) and analyzed with Scion image software.
Statistical Analysis
Data are expressed as mean 6 standard deviation (SD) of at least 3 independent experiments. Statistical differences were calculated using GraphPad Prism software (version 5.03). When absolute values of 2 means were compared, statistical significance was calculated by a Student t-test. When absolute values of more than 2 means were compared, statistical significance was calculated by a 1-way ANOVA followed by a Bonferroni post-hoc test. Statistical analysis was performed with a 1-sample t-test when relative values of the conditions were calculated by setting the control as 1 in each independent condition. In all cases, p < 0.05 was considered significant.
RESULTS
Increased Presence of Galectin-4 in Axons and Microglia/Macrophages Upon CuprizoneInduced Demyelination
To address a possible role of galectin-4 in OPC differentiation in remyelination, we first examined its presence in the well-established cuprizone experimental animal model of demyelination (54) . When mice were fed for 3 or 5 weeks with a diet containing 0.2% cuprizone, demyelinated areas, as visualized with LFB, were readily observed in the corpus callosum (Supplementary Data Fig. 1A) , and PLP mRNA in situ hybridizations demonstrated that OPCs were hardly differentiated (Supplementary Data Fig. 1B ). An increase of galectin-4 immunoreactivity was observed in the demyelinated areas at 3-and 5-week cuprizone feeding compared to the levels in control animals (Fig. 1A, B) . To visualize demyelinated areas, immunofluorescent analysis was combined with Sudan Black myelin staining, which reveals a demyelinated lesion as an unstained pale area. In control animals, galectin-4 is localized in the nucleus of cells which form linear pearls-on-a-string arrays, characteristic of interfascicular OLGs (Fig. 1A , cntrl inset, [55] ). A double labeling with the OLG lineage marker Olig2 showed that nuclear galectin-4 is present in Olig2-positive cells (Fig. 1A, inset) . Western blot analysis of homogenates of total dissected corpus callosum revealed a slight and consistent increase in galectin-4 expression in 5-week demyelinated corpus callosum compared to control total corpus callosum homogenates (Fig. 1C, D, arrow ). An additional galectin-4-immunoreactive band was visible at approximately 62 kDa (Fig. 1C, arrowhead) . The presence of this band has been reported before, while its origin (likely a dimer) or physiological significance is currently not yet clarified (27, 56, 57) . To assess whether galectin-4 is localized to axons, a double immunolabeling with the axonal marker neurofilament-H (NF-H) was performed. Consistent with its expression on naked axons during developmental myelination (27) , galectin-4 was localized to NF-H-positive axons at 5 weeks of cuprizoneinduced demyelination (Fig. 1E, arrow) . In addition, a more diffuse galectin-4 pattern around galectin-4-positive NF-Hpositive axons was noticed. Interestingly, not all NF-Hpositive axons were positive for galectin-4 (Fig. 1E , DM 5 wks, arrowhead), indicating that the expression of galectin-4 on axons may be not an immediate response to demyelination and/or transiently expressed. Of relevance in this respect is that previous in depth studies of the cuprizone model have demonstrated that between 3 and 5 weeks of cuprizone feeding myelin debris clearance parallels early processes of remyelination, while mature OLGs appear at 5.5 weeks even when cuprizone feeding is continued ( [58] , Supplementary Data Fig.  1B ). In addition to axonal staining, cells with a nuclear localization of galectin-4 were present in the demyelinated corpus callosum. Notably, in vitro galectin-4 is localized to the cytoplasm in OPCs, and only upon maturation of OLGs, cytoplasmic galectin-4 shifts to the nucleus (27) . As upon 5-week cuprizone feeding, mature OLGs are hardly present in the corpus callosum (58) we next assessed whether galectin-4 was detectable in microglia, which densely populate cuprizoneinduced demyelinated areas (Fig. 1F, [59, 60] ). Of note, while peripheral macrophages cross the blood-brain barrier upon cuprizone-mediated demyelination, they are by far outnumbered by resident microglia (61) . Microglia and macrophages were visualized by staining with the microglia/macrophage marker Iba1. Galectin-4 was present in the nucleus of Iba1-positive cells in the demyelinated areas of the corpus callosum at 5-week cuprizone feeding (Fig. 1F, arrow) , while 49.4% 6 7.0% of the galectin-4-positive cells were Iba1-positive. Hence, these data indicate that galectin-4 is present in both axons and microglia/macrophages in the corpus callosum upon cuprizone-induced demyelination.
Galectin-4 Is Transiently Expressed in Axons Upon Cuprizone-Induced Demyelination
To assess whether galectin-4, similar to developmental myelination (27) , is downregulated in axons upon remyelination, we next examined galectin-4 expression upon cessation of cuprizone feeding, which allows robust remyelination. Remyelination 2 weeks after cessation of cuprizone was confirmed by LFB staining, and PLP mRNA in situ hybridization revealed substantial OPC differentiation (Supplementary Data  Fig. 1 ). Upon 2 weeks of remyelination, galectin-4 immunoreactivity in NF-H-positive axons was absent, indicating that the increase in axonal galectin-4 levels upon demyelination was transient (Fig. 1E, RM 2 wks, arrow) . In fact, galectin-4 immunoreactivity in NF-H-positive axons was already lost after 2-day cuprizone cessation (Fig. 1G, RM 2 days) , similar to axonal galectin-4 expression in myelinating OLG-neuron cocultures at the onset of OPC differentiation (27) . At 7-day and 2-week remyelination, galectin-4-positive "strokes" were visible, which were not positive for the axonal marker NF-H (Fig. 1E, RM 2 wks; Fig. 1G, RM 7 days, arrowhead) . The total number of Iba1-positive cells was reduced at 2-week remyelination (Fig. 1F, 29 .6% 6 5.5% at DM 5 wks vs 20.1% 6 3.8% at RM 2 wks), consistent with previous findings (60) . Also, the number of galectin-4-positive cells that are Iba1-positive was reduced by approximately 50% (24.5% 6 1.9%), indicating that other cells than microglia/macrophages expressed galectin-4 in nucleus at remyelination. In fact, at 2-week remyelination, galectin-4 was present in nuclei of Iba1-negative cells that show a similar "lined" pattern as in control corpus callosum (Fig. 1F, arrowhead cf. Fig. 1A, cntrl) . Moreover, total galectin-4 immunoreactivity localized to the nucleus of cells in the corpus callosum was increased upon 2-week remyelination (respectively, 75.7% 6 6.9% RM 2 wks and 55.8% 6 8.0% DM 5 wks). Hence, these data indicate that galectin-4 is transiently present in the corpus callosum follow- 
Is Persistently Present in MS Lesions
ing cuprizone-induced demyelination, while its level is then subject to downregulation in axons at remyelination. To further examine whether upregulation of galectin-4 is a natural response to CNS injury, we next examined galectin-4 immunoreactivity in cr-EAE.
Galectin-4 Is Localized to Inflammatory Lesions in Spinal Cord of cr-EAE
cr-EAE is a widely accepted model that shares similarities with MS, including a multiphasic course, infiltration of CD68-positive mononuclear cells, early signs of demyelination mainly periventricularly and perivascularly, and axonal loss (62, 63) . At around days 12-13 after induction with recombinant MOG peptide, the animals undergo the first period of clinical symptoms ( Fig. 2A, phase I) , characterized by localized CD68-positive inflammatory infiltrates containing both infiltrated macrophages and activated resident microglia (63) . The infiltration phase was followed by a remission phase ( Fig. 2A, days 16-18 , phase II) and a relapse phase ( Fig. 2A , days 21-23, phase III). Demyelination is limited compared to the cuprizone model and tends to appear only during the second disease relapse, and likely represents early starting demyelinating areas (62) (63) (64) . Galectin-4 was readily seen in a rather diffuse pattern in spinal cord white matter at phase I of cr-EAE (Fig. 2B, phase I) , whereas controls presented no galectin-4 immunoreactivity in spinal cord white matter. The presence of galectin-4 was transient, as at the remission phase where the neurological score was almost as low as in controls, galectin-4 immunoreactivity was absent (Fig. 2B, phase II) . At the relapse phase, galectin-4 immunoreactivity reappeared, indicating a similar change in microenvironment at recurrent injury (Fig. 2B, phase III) . Analysis of serial sections stained for ED1, an antibody directed against rat CD68 and a marker for activated rat microglia, monocytes and macrophages (65) , showed that in the relapse phase galectin-4 was present in and around inflammatory infiltrates (Supplementary Data Fig. 2) . A fluorescent colabeling of galectin-4 and ED1 confirmed that galectin-4 was present in the cytoplasm of ED1-positive microglia/macrophages (Fig. 2C) . Not all galectin-4 colocalizes with microglia/macrophages, indicating that either other cell types than ED1-positive microglia/macrophages at the inflammatory infiltrates may harbor galectin-4 or it reflects secreted galectin-4. As galectin-4 is not detectable in serum at the relapse phase of cr-EAE (data not shown), the diffuse staining pattern of galectin-4 may reflect local externalization of galectin-4 rather than entry of galectin-4 via blood-brain barrier disruption. Remarkably, and in contrast to cuprizoneinduced demyelination, galectin-4 was only occasionally present in axons at the relapse phase (Supplementary Data Fig.  3 ). Taken together, consistent with cuprizone-induced demyelination, galectin-4 was transiently expressed during the inflammatory relapse phase, downregulated at the remission phase, and reappeared at the relapse phase. However, in contrast to cuprizone-induced demyelination, galectin-4 was more diffusely present at the infiltration phase, and mainly present in the cytoplasm of activated microglia/macrophages, rather than axons, at the relapse phase. To further examine a role for neuronal galectin-4 in demyelination, we next analyzed galectin-4 expression in demyelinated MS lesions, that is, in areas where remyelination fails.
Increased Galectin-4 Immunoreactivity in Axons and Activated Microglia/Macrophages in MS Lesions
In contrast to cr-EAE inflammatory demyelinating lesions, postmortem MS lesions are mostly demyelinated, as demonstrated by a lack of the myelin protein PLP (Fig. 3A,  B) . Active MS lesions were characterized by the prominent presence of MHC-II-positive cells at the center of lesions (Fig. 3A) , which were also present at the edge of chronic active lesions, but absent in chronic inactive MS lesions, the center of chronic active MS lesions, and control white matter (CWM, Fig. 3 ). Notable, MHC-II is a marker for antigenpresenting cells, which in active MS lesions mainly stains microglia/macrophages (66), and not OLGs and astrocytes (67, 68) . In CWM, a low level of expression of galectin-4 in axons (arrowhead) and in cells with typical microglia/macrophage morphology (arrow) was observed (Fig. 3B) . The number of galectin-4-positive axons increased in all examined active and chronic active MS lesions compared to CWM and to surrounding normal appearing white matter of MS patients (Fig. 3B, arrowhead) . Double immunolabeling with the axonal marker SMI-312 confirmed that galectin-4 was present in some axons in active MS lesions, and in most SMI-312- positive axons in chronic inactive MS lesions (Fig. 4A-C) . In contrast, SMI-312-positive axons in remyelinated lesions hardly showed galectin-4 immunoreactivity (Fig. 4D) . It should be noted that in active MS lesions ample active remyelination occurs (67) , while chronic inactive lesions may also contain areas of remyelination (3, 69) . In all examined active MS lesions, galectin-4 immunoreactivity was also observed in cells with a morphology that resembles activated microglia/ macrophages (Fig. 3B, arrow) . Indeed, with the use of MHC-II, the presence of galectin-4 in activated microglia/macrophages was ascertained (Fig. 4E ). Galectin-4 was only present in the cytoplasm of MHC-II-positive cells, while in others galectin-4 was detected in both cytoplasm and nucleus. In addition, occasionally MHC-II-negative cells with nuclear galectin-4 immunoreactivity were observed (Fig. 4E) . To gain further insight as to what type of microglia/macrophages express galectin-4 in active MS lesions, a double labeling of galectin-4 with an antibody against macrophage mannose receptor (CD206/MMR), a commonly used marker for remyelination-favoring alternatively activated microglia/macrophages was performed (70) . Virtually all CD206/MMRpositive microglia/macrophages harbored galectin-4 immunoreactivity in their cytoplasm and intensely in their nuclei (Fig. 4F, arrowhead) . However, not all galectin-4-positive cells were CD206/MMR-positive, indicating that the presence of galectin-4 was not restricted to cells expressing CD206/ MMR. Hence, as observed in cuprizone-induced demyelinated white matter, galectin-4 was expressed in both axons and activated microglia/macrophages in demyelinated white matter MS lesions. Notably, in contrast to previous findings and in control tissue of young adult mice ( Fig. 1) and rats ( Fig. 2) , some axons harbor galectin-4 in human CWM, which may relate to age-related loss of myelinated fibers and the decreased ability to remyelinate upon aging (71) (72) (73) or to species differences. As our findings clearly identify the presence of galectin-4 in microglia/macrophages upon demyelination and as galectin-4 is absent in microglia upon developmental myelination (27), we next addressed the question whether exogenous galectin-4 is imported by microglia/macrophages.
IFN-c/LPS-and IL-4-Activated BMDMs Import Galectin-4 in a Carbohydrate-Dependent Manner
To evaluate the presence of galectin-4 in microglia/macrophages upon demyelination and given the presence of galectin-4 in cytoplasm of microglia/macrophages in MS lesions, we determined whether the presence of galectin-4 in these cells may be a result of uptake of galectin-4, secreted from axons. As a major part of the activated macrophages in active MS lesions are derived from infiltrated macrophages (74) , and microglia and macrophages may have unique roles in MS lesions development (75, 76) , we assessed galectin-4 uptake in BMDMs. To this end, cultured naïve BMDMs were treated In both BMDM activation states, galectin-4 uptake was inhibited upon addition of a mixture of lactose and ASF, which inhibits carbohydrate-dependent binding of the lectin (Fig. 5A, [51] ). This suggests that uptake of galectin-4 by BMDMs requires cell binding via glycans to make endocytosis possible. Live labeling with biotinylated-galectin-4 at 4 C showed that IFN-c/LPS-activated and IL-4-activated rat BMDMs had galectin-4-binding sites at their cell surface and that galectin-4 binding was carbohydrate inhibitable (Fig. 5B, C) . Approximately 80% of the cells in either activation state displayed galectin-4 binding sites, which was reduced to approximately 10%-20% in the presence of the mixture of cognate glycan. Therefore, macrophages may scavenge galectin-4 from the environment, for example, to prevent its binding to OLGs. Looking at cell stimulation, a particular microglia/macrophage activation state that is of relevance for de-and remyelination may endogenously express galectin-4, which is a hypothesis that was examined next.
Galectin-4 Expression Is Enhanced in IL-4-Activated Microglia and BMDMs
To evaluate whether BMDMs and microglia endogenously express galectin-4, Western blot analysis on monocultures was performed. Galectin-4 protein levels were significantly upregulated in alternatively IL-4-activated BMDMs and microglia compared to IFN-c/LPS-activated and naïve BMDMs and microglia (Fig. 6A-D) . The activation de
states were verified by measuring expression of iNOS and arginase, which are markers for classically or alternatively activated BMDMs and microglia, respectively (77) (78) (79) . Western blot analysis of conditioned medium provided no evidence for detectable galectin-4, suggesting that the levels of secreted galectin-4 were very low, or, more likely, that galectin-4 was not secreted (Fig. 6E) . In contrast, galectin-3 was secreted by BMDMs and microglia (Fig. 6E) , as described (80) (81) (82) . Immunocytochemical analysis showed that galectin-4 was localized to the cytoplasm and nucleus in IL-4-activated BMDMs and microglia (Fig. 6F) . Upon IFN-c/LPS activation, galectin-4 was also present, although to a lesser extent, in the cytoplasm and nucleus of IFN-c/LPS-activated BMDMs, whereas galectin-4 appeared to be restricted to the cytoplasm in IFN-c/ LPS-activated microglia. In conclusion, galectin-4 expression was significantly enhanced in IL-4-activated BMDMs and microglia. However, galectin-4 was not secreted by BMDMs and microglia. Thus, in contrast to axonal-derived galectin-4, the microglia/macrophage galectin-4 likely does not affect OLG differentiation via its secretion.
DISCUSSION
Understanding the process of remyelination and why it fails in MS may provide targets for remyelination-based therapies that preserves axons and halts disease progression. Here, we show that galectin-4, a soluble negative neuronal regulator of myelination (27) , was transiently reappeared in axons of the corpus callosum upon cuprizone-induced demyelination, while galectin-4 was persistently present in axons of chronic MS lesions. Galectin-4 was also detected in the nucleus of activated microglia/macrophages in cuprizonedemyelinated areas, and in the cytoplasm and nuclei of activated microglia/macrophages in active MS lesions. In vitro analyses revealed that galectin-4 resided in BMDMs, following endocytosis in a carbohydrate-inhibitable manner, while IL-4-mediated activation towards alternatively activated BMDMs and microglia induced the expression of endogenous galectin-4. Thus, these findings suggest that, similar to developmental myelination, neuronal galectin-4 may play a regulatory role in the fine-tuning of OPC differentiation upon demyelination involving activated microglia/ macrophages, which may remove secreted galectin-4 from the environment preventing its action on immature OLGs (Fig. 7) . Whether galectin-4 is also taken up by astrocytes and whether endogenous galectin-4 in microglia/macrophages is important for remyelination to occur, for example, via modulating the production and/or release of promyelinating factors, remain to be determined (Fig. 7) . During CNS development, the disappearance of neuronal galectin-4 is coincident with the initiation of myelination (27) . The present study showed a similar inverse correlation between axonal galectin-4 and the initiation of remyelination. Also, in demyelinated chronic inactive and, to a lesser extent in active white matter MS lesions, axons showed strong intensity of galectin-4 immunoreactivity. Interestingly, not all axons in active MS lesions and in cuprizone-demyelinated corpus callosum were galectin-4 positive. In addition, galectin-4 was only occasionally expressed in axons at inflammatory infiltrates in the cr-EAE animal model. This indicates that the observed presence of galectin-4 in demyelinated areas is likely not an immediate response to demyelination. Alternatively, the absence of axonal galectin-4 in cr-EAE may partially be explained by the still-limited and ongoing demyelination (62, 63, 83) . Indeed, during development only nonmyelinated axon segments contain galectin-4, while neuronal galectin-4 is segregated from myelinated axons (41) . The presence of axonal galectin-4 upon cuprizone-induced demyelination was transient, that is, axonal galectin-4 expression was downregulated upon remyelination. Hence, the absence of axonal galectin-4 in some axons may also reflect early remyelination events or successful remyelination. In contrast, in chronic MS lesions where remyelination fails, axonal galectin-4 expression was maintained. Given the negative regulatory role of neuronal galectin-4 in the timing of myelination (27) , the transient presence upon demyelination at nonpathological conditions suggests a similar role of galectin-4 in the fine-tuning of remyelination. The persistent presence of axonal galectin-4 in chronic MS lesions may contribute to the quiescence of OPCs, and therefore remyelination failure (Fig. 7) . Re-expression of an axonal protein that acts as an inhibitor of developmental myelination is not unique, as other negative regulators of OLG differentiation are re-expressed upon demyelination. For example, the neural cell adhesion molecule polysialyated-neuronal cell adhesion molecule is re-expressed by demyelinated axons upon demyelination and is present in MS lesions (21) . Also leucine rich repeat and immunoglobulinlike domain containing protein-1 (LINGO-1) is re-expressed upon demyelination, and the functional inhibition of LINGO-1 promotes remyelination upon toxin-induced demyelination (11, 22) . To what extent re-expressed galectin-4 is secreted by demyelinated axons and/or is able to localize the adhesion molecule L1 at the axonal membrane for functional interaction with oligodendroglial F3/contactin (38) and, in this way, fine-tune the remyelination process remains to be established. In addition, it will be of interest to examine whether upon demyelination similar galectin-4 containing domains will be formed on axonal membranes, as observed during neuronal development that locally determine myelin-free axon segments (41) .
In addition to its presence in axons, galectin-4 was also detected in activated microglia/macrophages upon cuprizoneinduced demyelination, in active MS lesions and in inflammatory infiltrates in cr-EAE. While no specific markers for either microglia or macrophages were used, it is likely that in vivo both activated resident microglia and infiltrated macrophages harbor galectin-4. Microglia outnumber infiltrated macrophages in cuprizone-induced lesions (59) (60) (61) , and infiltrated macrophages are prominently present in cr-EAE and MS lesions (63, 74) . Also, in active MS lesions, it is estimated that 45% of the macrophages are derived from activated resident microglia and 55% from infiltrated monocytes/macrophages (74) . The presence of galectin-4 in activated microglia was caused by an upregulation, as galectin-4 protein is hardly detected in microglia in brain tissue during development (27) . Our in vitro analysis showed that both classically IFN-c/LPSand alternatively IL-4-activated BMDMs had galectin-4-binding sites at their surface and that galectin-4 was taken up by either type of macrophage in a carbohydrate inhibitable manner. This in part may explain the localization of galectin-4 in the cytoplasm of microglia/macrophages in MS lesions. Potentially, given the presence of galectin-4-binding sites on BMDMs, galectin-4 secreted by neurons may modulate macrophage activation and function, as has also been reported for an oxidized form of galectin-1, which is monomeric and has lost lectin activity (84) . In addition, galectin-4 is known as potent modulator of the proteome of colon cancer cells at multiple sites, for example, binding of galectin-4 to the cell surface increased expression of proteins related to secretory and transport functions (85) . Also, exogenous addition of galectin-4 to blood-derived macrophages increases the secretion of tumor necrosis factor a and IL-10 and regulates T-cell function by macrophage priming (86) . Our preliminary findings showed that iNOS and arginase expression was not altered by galectin-4 treatment or galectin-4 overexpression (data not shown), suggesting that (neuronal) galectin-4 does not drastically alter or switch these markers of the activation state of macrophages. Of interest, in mice with induced colitis, galectin-4 has been linked to stimulate IL-6 production by CD4-positive cells only under inflammatory conditions (87) . Galectin-4 may play a similar role during inflammatory processes in MS lesions, and its effective endocytosis may preclude its effect on OLGs as noted earlier.
Galectin-4 was also present in ED1-positive microglia/ macrophages at the relapse phase of cr-EAE with less prominent expression of axonal galectin-4. This indicates that the expression of galectin-4 in microglia/macrophages is likely an immediate endogenous response to CNS injury. Indeed, our previous findings demonstrate that galectin-4 mRNA is hardly detectable in postmortem MS lesions, whereas galectin-1, -3, and -8 mRNA levels were enhanced (44) . Upon cuprizonemediated demyelination where a remyelination-supportive microglia/macrophage phenotype is predominant (26), galectin-4 was mainly localized to the nucleus of microglia/ macrophages in the demyelinated areas of the corpus callosum. Our in vitro findings demonstrate that galectin-4 was expressed, but not released by BMDMs and microglia, with an increased expression of galectin-4 in alternatively IL-4-activated BMDMs and microglia, a phenotype that is supportive for remyelination (25) . Remarkably, galectin-4 was localized to the cytoplasm and nucleus in IL-4-activated BMDMs and microglia. In MS lesions, galectin-4 was present both in the cytoplasm and nucleus of alternatively activated CD206/ MMR-positive microglia/macrophages. In comparison, the majority of galectin-4-positive CD206/MMR-negative microglia/macrophages had galectin-4 in their cytoplasm, as also observed for cultured IFN-c/LPS-activated microglia. This suggests an additional role of endogenous (nuclear) galectin-4, most likely in gene transcription regulation, in alternatively activated microglia/macrophages in addition to scavenging neuronal galectin-4 from OLGs. Notably, nuclear presence of galectins is a frequently encountered phenomenon, and cytoplasmic to nuclear translocation of galectin-4 has been documented upon OPC differentiation (27, 42) and in the rat small intestine (88) . In mature OLGs, nuclear galectin-4 binds to both glycosylated p27 and Sp1, the latter associating with the MBP promoter (42) . Hence, the observed increased number of Iba-1-negative cells that showed galectin-4 immunoreactivity in the nucleus upon remyelination following cuprizoneinduced demyelination may represent differentiated OLGs. How galectin-4 is targeted to the nucleus in microglia/macrophages and in OLGs remains to be determined. Taken together, in addition to axonal adhesive signals in MS, demyelinated axons in MS lesions persistently express and likely secrete galectin-4, what may contribute to prevent OPC differentiation (Fig. 7) . In the majority of microglia/ (89, 90) , the number of microglia/macrophages with nuclear positivity for galectin-4 is decreased; all of these events may prevent OPC maturation and contribute to remyelination failure.
de Jong et al J Neuropathol Exp Neurol • Volume 77, Number 11, November 2018 macrophages in MS lesions, galectin-4 was present in the cytoplasm, rather than in the nucleus as observed upon cuprizone-induced demyelination. This finding may be related to the fact that microglia/macrophages do not fully reach the alternatively activated state in MS lesions (89, 90) . This may also contribute to the inhibition of OPC differentiation (Fig. 7) . Therefore, the observed persistence of re-expressed neuronal galectin-4 and the absence of nuclear galectin-4 in most microglia/macrophages may be involved in the disruption of the remyelination process and play a part in the disease progression of MS. Hence, pharmacological modulation of galectin-4 function at this site may be envisioned to represent a novel therapeutic strategy to overcome remyelination failure.
